Indoleamine 2,3-dioxygenase

Last updated
IDO1
IDO1 prot.png
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases IDO1 , IDO, IDO-1, INDO, indoleamine 2,3-dioxygenase 1
External IDs OMIM: 147435 MGI: 96416 HomoloGene: 48082 GeneCards: IDO1
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_002164

NM_008324
NM_001293690

RefSeq (protein)

NP_002155

NP_001280619
NP_032350

Location (UCSC) Chr 8: 39.9 – 39.93 Mb Chr 8: 25.07 – 25.09 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse
Indoleamine 2,3-dioxygenase
PDB 2d0t EBI.jpg
crystal structure of 4-phenylimidazole bound form of human indoleamine 2,3-dioxygenase
Identifiers
SymbolIDO
Pfam PF01231
Pfam clan CL0380
InterPro IPR000898
PROSITE PDOC00684
Available protein structures:
Pfam   structures / ECOD  
PDB RCSB PDB; PDBe; PDBj
PDBsum structure summary
Indoleamine 2,3-dioxygenase
Identifiers
EC no. 1.13.11.52
CAS no. 9014-51-1
Databases
IntEnz IntEnz view
BRENDA BRENDA entry
ExPASy NiceZyme view
KEGG KEGG entry
MetaCyc metabolic pathway
PRIAM profile
PDB structures RCSB PDB PDBe PDBsum
Gene Ontology AmiGO / QuickGO
Search
PMC articles
PubMed articles
NCBI proteins

Indoleamine-pyrrole 2,3-dioxygenase (IDO or INDO EC 1.13.11.52) is a heme-containing enzyme physiologically expressed in a number of tissues and cells, such as the small intestine, lungs, female genital tract or placenta. [5] In humans is encoded by the IDO1 gene. [6] IDO is involved in tryptophan metabolism. It is one of three enzymes that catalyze the first and rate-limiting step in the kynurenine pathway, the O2-dependent oxidation of L-tryptophan to N-formylkynurenine, the others being indolamine-2,3-dioxygenase 2 (IDO2) [7] and tryptophan 2,3-dioxygenase (TDO). [8] IDO is an important part of the immune system and plays a part in natural defense against various pathogens. [9] [10] It is produced by the cells in response to inflammation and has an immunosuppressive function because of its ability to limit T-cell function and engage mechanisms of immune tolerance. [11] Emerging evidence suggests that IDO becomes activated during tumor development, helping malignant cells escape eradication by the immune system. Expression of IDO has been described in a number of types of cancer, such as acute myeloid leukemia, ovarian cancer or colorectal cancer. IDO is part of the malignant transformation process and plays a key role in suppressing the anti-tumor immune response in the body, so inhibiting it could increase the effect of chemotherapy as well as other immunotherapeutic protocols. [12] [13] [14] Furthermore, there is data implicating a role for IDO1 in the modulation of vascular tone in conditions of inflammation via a novel pathway involving singlet oxygen. [15]

Physiological function

Indoleamine 2,3-dioxygenase is the first and rate-limiting enzyme of tryptophan catabolism through the kynurenine pathway.

IDO is an important molecule in the mechanisms of tolerance and its physiological functions include the suppression of potentially dangerous inflammatory processes in the body. [16] IDO also plays a role in natural defense against microorganisms. Expression of IDO is induced by interferon-gamma, which explains why the expression increases during inflammatory diseases or even during tumorigenesis. [17] Since tryptophan is essential for the survival of pathogens, the activity of enzyme IDO destroys them. Microorganisms susceptible to tryptophan deficiency include bacteria of genus Streptococcus [18] or viruses such as herpes simplex [19] or measles. [20]

One of the organs with high IDO expression is the placenta. In the 1990s, the immunosuppressive function of this enzyme was first described in mice due to the study of placental tryptophan metabolism. Thus, mammalian placenta, due to intensive tryptophan catabolism has the ability to suppress T cell activity, thereby contributing to its position of immunologically privileged tissue. [21]

Clinical significance

IDO is an immune checkpoint molecule in the sense that it is an immunomodulatory enzyme produced by alternatively activated macrophages and other immunoregulatory cells. [22] IDO is known to suppress T and NK cells, generate Tregs and myeloid-derived suppressor cells, and also supports angiogenesis. [12]

These mechanisms are crucial in the process of carcinogenesis. IDO allows tumor cells to escape the immune system by two main mechanisms. The first mechanism is based on tryptophan depletion from the tumor microenvironment. [23] The second mechanism is based on the production of catabolic products called kynurenins, that are cytotoxic for T lymphocytes and NK cells. [24] Overexpression of human IDO (hIDO) is described in a variety of human tumor cell lineages and is often associated with poor prognosis. [25] [26] Tumors with increased production of IDO include prostate, ovarian, lung or pancreatic cancer or acute myeloid leukemia. [27] [28] Expression of IDO is under physiological conditions regulated by the Bin1 gene, which can be damaged by tumor transformation. [29]

Emerging clinical studies suggest that combination of IDO inhibitors with classical chemotherapy and radiotherapy could restore immune control and provide a therapeutic response to generally resistant tumors. Enzyme IDO used by tumors to escape immune surveillance is currently in focus of research and drug discovery efforts, [30] as well as efforts to understand if it could be used as a biomarker for prognosis. [31]

Inhibitors

COX-2 inhibitors down-regulate indoleamine 2,3-dioxygenase, leading to a reduction in kynurenine levels as well as reducing proinflammatory cytokine activity.[ citation needed ]

1-Methyltryptophan is a racemic compound that weakly inhibits indoleamine dioxygenase, but is also a very slow substrate. The specific racemer 1-methyl-D-tryptophan (known as indoximod) is in clinical trials for various cancers.

Epacadostat (INCB24360), navoximod (GDC-0919), and linrodostat (BMS-986205) are potent inhibitors of the indoleamine 2,3-dioxygenase enzyme and are in clinical trials for various cancers.

See also

Related Research Articles

Stromal cells, or mesenchymal stromal cells, are differentiating cells found in abundance within bone marrow but can also be seen all around the body. Stromal cells can become connective tissue cells of any organ, for example in the uterine mucosa (endometrium), prostate, bone marrow, lymph node and the ovary. They are cells that support the function of the parenchymal cells of that organ. The most common stromal cells include fibroblasts and pericytes. The term stromal comes from Latin stromat-, "bed covering", and Ancient Greek στρῶμα, strôma, "bed".

<span class="mw-page-title-main">Interferon gamma</span> InterPro Family

Interferon gamma (IFN-γ) is a dimerized soluble cytokine that is the only member of the type II class of interferons. The existence of this interferon, which early in its history was known as immune interferon, was described by E. F. Wheelock as a product of human leukocytes stimulated with phytohemagglutinin, and by others as a product of antigen-stimulated lymphocytes. It was also shown to be produced in human lymphocytes. or tuberculin-sensitized mouse peritoneal lymphocytes challenged with Mantoux test (PPD); the resulting supernatants were shown to inhibit growth of vesicular stomatitis virus. Those reports also contained the basic observation underlying the now widely employed IFN-γ release assay used to test for tuberculosis. In humans, the IFN-γ protein is encoded by the IFNG gene.

<span class="mw-page-title-main">Kynurenine</span> Chemical compound

l-Kynurenine is a metabolite of the amino acid l-tryptophan used in the production of niacin.

The Eutherian Fetoembryonic Defense System(eu-FEDS) is a hypothetical model describing a method by which immune systems are capable of recognizing additional states of relatedness like "own species" such as is observed in maternal immune tolerance in pregnancy. The model includes descriptions of the proposed signaling mechanism and several proposed examples of exploitation of this signaling in disease states.

<span class="mw-page-title-main">CD86</span> Mammalian protein found in Homo sapiens

Cluster of Differentiation 86 is a protein constitutively expressed on dendritic cells, Langerhans cells, macrophages, B-cells, and on other antigen-presenting cells. Along with CD80, CD86 provides costimulatory signals necessary for T cell activation and survival. Depending on the ligand bound, CD86 can signal for self-regulation and cell-cell association, or for attenuation of regulation and cell-cell disassociation.

<span class="mw-page-title-main">Lankenau Institute for Medical Research</span>

Lankenau Institute for Medical Research (LIMR), founded in 1927, is a nonprofit, biomedical research institute located on the campus of Lankenau Medical Center in Wynnewood, Pennsylvania, serving as the research division of the Main Line Health System in suburban Philadelphia. LIMR focuses on studies of cancer, cardiovascular, autoimmune, gastrointestinal and other diseases. It houses a center for population health research.

<i>N</i>-Formylkynurenine Chemical compound

N-Formylkynurenine is an intermediate in the catabolism of tryptophan. It is a formylated derivative of kynurenine. The formation of N-formylkynurenine is catalyzed by heme dioxygenases.

<span class="mw-page-title-main">Tryptophan 2,3-dioxygenase</span> Mammalian protein found in Homo sapiens

In enzymology, tryptophan 2,3-dioxygenase (EC 1.13.11.11) is a heme enzyme that catalyzes the oxidation of L-tryptophan (L-Trp) to N-formyl-L-kynurenine, as the first and rate-limiting step of the kynurenine pathway.

<span class="mw-page-title-main">PD-L1</span> Mammalian protein found in Homo sapiens

Programmed death-ligand 1 (PD-L1) also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1) is a protein that in humans is encoded by the CD274 gene.

Chronic systemic inflammation (SI) is the result of release of pro-inflammatory cytokines from immune-related cells and the chronic activation of the innate immune system. It can contribute to the development or progression of certain conditions such as cardiovascular disease, cancer, diabetes mellitus, chronic kidney disease, non-alcoholic fatty liver disease, autoimmune and neurodegenerative disorders, and coronary heart disease.

<span class="mw-page-title-main">Dioxygenase</span> Class of enzymes

Dioxygenases are oxidoreductase enzymes. Aerobic life, from simple single-celled bacteria species to complex eukaryotic organisms, has evolved to depend on the oxidizing power of dioxygen in various metabolic pathways. From energetic adenosine triphosphate (ATP) generation to xenobiotic degradation, the use of dioxygen as a biological oxidant is widespread and varied in the exact mechanism of its use. Enzymes employ many different schemes to use dioxygen, and this largely depends on the substrate and reaction at hand.

<span class="mw-page-title-main">Quinolinic acid</span> Dicarboxylic acid with pyridine backbone

Quinolinic acid, also known as pyridine-2,3-dicarboxylic acid, is a dicarboxylic acid with a pyridine backbone. It is a colorless solid. It is the biosynthetic precursor to niacin.

<span class="mw-page-title-main">KMO (gene)</span> Protein-coding gene in the species Homo sapiens

Kynurenine 3-monooxygenase is an enzyme that in humans is encoded by the KMO gene.

<span class="mw-page-title-main">Kynurenine pathway</span> Metabolic pathway that produces the NAD coenzyme

The kynurenine pathway is a metabolic pathway leading to the production of nicotinamide adenine dinucleotide (NAD+). Metabolites involved in the kynurenine pathway include tryptophan, kynurenine, kynurenic acid, xanthurenic acid, quinolinic acid, and 3-hydroxykynurenine. The kynurenine pathway is responsible for total catabolization of tryptophan about 95%. Disruption in the pathway is associated with certain genetic and psychiatric disorders.

<span class="mw-page-title-main">1-Methyltryptophan</span> Chemical compound

1-Methyltryptophan is a chemical compound that is an inhibitor of the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase. It is a chiral compound that can exist as both D- and L-enantiomers.

<span class="mw-page-title-main">George C. Prendergast</span> American biomedical scientist

George C. Prendergast is an American biomedical scientist. His research has focused on cancer pathobiology and immunology. Since 2004, he has been the President and CEO of Lankenau Institute for Medical Research, a cancer-focused research center in the U.S. He is also the co-director of the Program in Cancer Cell Biology & Signaling at the Sidney Kimmel Cancer Center, Thomas Jefferson University.

<span class="mw-page-title-main">Immune checkpoint</span> Regulators of the immune system

Immune checkpoints are regulators of the immune system. These pathways are crucial for self-tolerance, which prevents the immune system from attacking cells indiscriminately. However, some cancers can protect themselves from attack by stimulating immune checkpoint targets.

Immuno-psychiatry, according to Pariante, is a discipline that studies the connection between the brain and the immune system. It differs from psychoneuroimmunology by postulating that behaviors and emotions are governed by peripheral immune mechanisms. Depression, for instance, is seen as malfunctioning of the immune system.

<span class="mw-page-title-main">Indoleamine 2,3-dioxygenase 2</span> Protein-coding gene in the species Homo sapiens

Indoleamine 2,3-dioxygenase 2 (IDO2) is a protein that in humans is encoded by the IDO2 gene.

<span class="mw-page-title-main">Linrodostat</span> Chemical compound

Linrodostat is an experimental drug being studied for its immunomodulating and antineoplastic activities.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000131203 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000031551 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. Yamazaki F, Kuroiwa T, Takikawa O, Kido R (September 1985). "Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme". The Biochemical Journal. 230 (3): 635–8. doi:10.1042/bj2300635. PMC   1152665 . PMID   3877502.
  6. "Entrez Gene: INDO indoleamine-pyrrole 2,3 dioxygenase".
  7. Prendergast GC, Metz R, Muller AJ, Merlo LM, Mandik-Nayak L (2014-11-20). "IDO2 in Immunomodulation and Autoimmune Disease". Frontiers in Immunology. 5: 585. doi: 10.3389/fimmu.2014.00585 . PMC   4238401 . PMID   25477879.
  8. Badawy AA, Bano S (January 2016). "Tryptophan Metabolism in Rat Liver After Administration of Tryptophan, Kynurenine Metabolites, and Kynureninase Inhibitors". International Journal of Tryptophan Research. 9: 51–65. doi:10.4137/ijtr.s38190. PMC   4982523 . PMID   27547037.
  9. Yoshida R, Hayaishi O (August 1978). "Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide". Proceedings of the National Academy of Sciences of the United States of America. 75 (8): 3998–4000. Bibcode:1978PNAS...75.3998Y. doi: 10.1073/pnas.75.8.3998 . PMC   392917 . PMID   279015.
  10. Yoshida R, Urade Y, Tokuda M, Hayaishi O (August 1979). "Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection". Proceedings of the National Academy of Sciences of the United States of America. 76 (8): 4084–6. Bibcode:1979PNAS...76.4084Y. doi: 10.1073/pnas.76.8.4084 . PMC   383982 . PMID   291064.
  11. Munn DH, Mellor AL (March 2013). "Indoleamine 2,3 dioxygenase and metabolic control of immune responses". Trends in Immunology. 34 (3): 137–43. doi:10.1016/j.it.2012.10.001. PMC   3594632 . PMID   23103127.
  12. 1 2 Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ (July 2014). "Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer". Cancer Immunology, Immunotherapy. 63 (7): 721–35. doi:10.1007/s00262-014-1549-4. PMC   4384696 . PMID   24711084.
  13. Munn DH, Mellor AL (March 2016). "IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance". Trends in Immunology. 37 (3): 193–207. doi:10.1016/j.it.2016.01.002. PMC   4916957 . PMID   26839260.
  14. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. (October 2003). "Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase". Nature Medicine. 9 (10): 1269–74. doi:10.1038/nm934. PMID   14502282. S2CID   10618102.
  15. Stanley CP, Maghzal GJ, Ayer A, Talib J, Giltrap AM, Shengule S, et al. (February 2019). "Singlet molecular oxygen regulates vascular tone and blood pressure in inflammation". Nature. 566 (7745): 548–552. Bibcode:2019Natur.566..548S. doi:10.1038/s41586-019-0947-3. hdl:1959.17/169229. PMID   30760924. S2CID   61156683.
  16. Romani L, Fallarino F, De Luca A, Montagnoli C, D'Angelo C, Zelante T, et al. (January 2008). "Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease". Nature. 451 (7175): 211–5. Bibcode:2008Natur.451..211R. doi:10.1038/nature06471. PMID   18185592. S2CID   4391121.
  17. Mellor AL, Lemos H, Huang L (2017-10-27). "Indoleamine 2,3-Dioxygenase and Tolerance: Where Are We Now?". Frontiers in Immunology. 8: 1360. doi: 10.3389/fimmu.2017.01360 . PMC   5663846 . PMID   29163470.
  18. MacKenzie CR, Hadding U, Däubener W (September 1998). "Interferon-gamma-induced activation of indoleamine 2,3-dioxygenase in cord blood monocyte-derived macrophages inhibits the growth of group B streptococci". The Journal of Infectious Diseases. 178 (3): 875–8. doi: 10.1086/515347 . PMID   9728563.
  19. Adams O, Besken K, Oberdörfer C, MacKenzie CR, Takikawa O, Däubener W (March 2004). "Role of indoleamine-2,3-dioxygenase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections". Journal of Virology. 78 (5): 2632–6. doi:10.1128/jvi.78.5.2632-2636.2004. PMC   369218 . PMID   14963171.
  20. Obojes K, Andres O, Kim KS, Däubener W, Schneider-Schaulies J (June 2005). "Indoleamine 2,3-dioxygenase mediates cell type-specific anti-measles virus activity of gamma interferon". Journal of Virology. 79 (12): 7768–76. doi:10.1128/jvi.79.12.7768-7776.2005. PMC   1143631 . PMID   15919929.
  21. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, et al. (August 1998). "Prevention of allogeneic fetal rejection by tryptophan catabolism". Science. 281 (5380): 1191–3. Bibcode:1998Sci...281.1191M. doi:10.1126/science.281.5380.1191. PMID   9712583.
  22. Moon YW, Hajjar J, Hwu P, Naing A (2015). "Targeting the indoleamine 2,3-dioxygenase pathway in cancer". Journal for Immunotherapy of Cancer. 3: 51. doi: 10.1186/s40425-015-0094-9 . PMC   4678703 . PMID   26674411.
  23. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL (1999-05-03). "Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism". The Journal of Experimental Medicine. 189 (9): 1363–1372. doi: 10.1084/jem.189.9.1363 . ISSN   0022-1007. PMC   2193062 . PMID   10224276.
  24. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB (2002-08-12). "Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase". The Journal of Experimental Medicine. 196 (4): 459–468. doi: 10.1084/jem.20020121 . ISSN   1540-9538. PMC   2196046 . PMID   12186838.
  25. Okamoto A, Nikaido T, Ochiai K, Takakura S, Takao M, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O (November 2007). "Ido serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells". International Congress Series. 1304: 262–273. doi:10.1016/j.ics.2007.07.053. ISSN   0531-5131.
  26. Inaba T, Ino K, Kajiyama H, Shibata K, Yamamoto E, Kondo S, Umezu T, Nawa A, Takikawa O, Kikkawa F (June 2010). "Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy". Gynecologic Oncology. 117 (3): 423–428. doi:10.1016/j.ygyno.2010.02.028. ISSN   0090-8258. PMID   20350764.
  27. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003-09-21). "Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase". Nature Medicine. 9 (10): 1269–1274. doi:10.1038/nm934. ISSN   1078-8956. PMID   14502282. S2CID   10618102.
  28. Jiang T, Sun Y, Yin Z, Feng S, Sun L, Li Z (February 2015). "Research progress of indoleamine 2,3-dioxygenase inhibitors". Future Medicinal Chemistry. 7 (2): 185–201. doi:10.4155/fmc.14.151. ISSN   1756-8919. PMID   25686005.
  29. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC (2005-02-13). "Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy". Nature Medicine. 11 (3): 312–319. doi:10.1038/nm1196. ISSN   1078-8956. PMID   15711557. S2CID   12338548.
  30. Jiang T, Sun Y, Yin Z, Feng S, Sun L, Li Z (2015). "Research progress of indoleamine 2,3-dioxygenase inhibitors". Future Medicinal Chemistry. 7 (2): 185–201. doi:10.4155/fmc.14.151. PMID   25686005.
  31. Yu CP, Fu SF, Chen X, Ye J, Ye Y, Kong LD, Zhu Z (2018). "The Clinicopathological and Prognostic Significance of IDO1 Expression in Human Solid Tumors: Evidence from a Systematic Review and Meta-Analysis". Cellular Physiology and Biochemistry. 49 (1): 134–143. doi: 10.1159/000492849 . PMID   30134237.